



# IDSAs

Infectious Diseases Society of America

## 2013-2014 BOARD OF DIRECTORS

President  
**Barbara E. Murray, MD, FIDSA**  
THE UNIVERSITY OF TEXAS HEALTH  
SCIENCE CENTER  
HOUSTON, TX

President-Elect  
**Stephen B. Calderwood, MD, FIDSA**  
MASSACHUSETTS GENERAL HOSPITAL  
BOSTON, MA

Vice President  
**Johan S. Bakken, MD, PhD, FIDSA**  
ST. LUKE'S ID ASSOCIATES  
DULUTH, MN

Secretary  
**Penelope H. Dennehy, MD, FIDSA**  
HASBRO CHILDREN'S HOSPITAL  
PROVIDENCE, RI

Treasurer  
**Cynthia L. Sears, MD, FIDSA**  
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE  
BALTIMORE, MD

Immediate Past President  
**David A. Relman, MD, FIDSA**  
STANFORD UNIVERSITY SCHOOL OF MEDICINE  
PALO ALTO, CA

**Judith A. Aberg, MD, FIDSA**  
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI  
NEW YORK, NY

**Barbara D. Alexander, MD, MHS,  
FIDSA**  
DUKE UNIVERSITY MEDICAL CENTER  
DURHAM, NC

**Upton D. Allen, MD, FIDSA**  
HOSPITAL FOR SICK CHILDREN  
TORONTO, ONTARIO, CANADA

**Helen W. Boucher, MD, FIDSA**  
TUFTS MEDICAL CENTER  
BOSTON, MA

**R. Michael Buckley, MD, FIDSA**  
UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM  
PHILADELPHIA, PA

**Deborah Cotton, MD, MPH, FIDSA**  
BOSTON UNIVERSITY SCHOOL OF MEDICINE  
BOSTON, MA

**Stanley C. Deresinski, MD, FIDSA**  
STANFORD UNIVERSITY SCHOOL OF MEDICINE  
PALO ALTO, CA

**Louis B. Rice, MD**  
WARREN ALPERT MEDICAL SCHOOL  
OF BROWN UNIVERSITY  
PROVIDENCE, RI

**Steven K. Schmitt, MD, FIDSA**  
CLEVELAND CLINIC  
CLEVELAND, OH

Chief Executive Officer  
**Mark A. Leasure**

**IDSAs Headquarters**  
1300 Wilson Boulevard  
Suite 300  
Arlington, VA 22209  
**TEL:** (703) 299-0200  
**FAX:** (703) 299-0204  
**EMAIL ADDRESS:**  
info@idsociety.org  
**WEBSITE:**  
www.idsociety.org

January 22, 2014

Division of Dockets Management (HFA-305)  
Food and Drug Administration  
5630 Fishers Lane, Rm. 1061  
Rockville, MD 20852

Re: Comments on Docket No. FDA-2013-D-1319; Draft Guidance for Industry on  
Pulmonary Tuberculosis: Developing Drugs for Treatment; Availability

Dear Sir/Madam:

On behalf of the Infectious Diseases Society of America (IDSAs), thank you for the opportunity to respond to FDA's draft guidance for industry, entitled "Pulmonary Tuberculosis: Developing Drugs for Treatment." IDSAs represents more than 10,000 physicians, scientists and other health care professionals devoted to excellence in patient care, prevention, public health, education, and research related to infectious diseases (ID) including tuberculosis. Our members care for tuberculosis (TB) patients directly, provide ID consultation to providers for TB and related co-infections, and conduct TB clinical trials, including through the Centers for Disease Control & Prevention's (CDC) TB Trials Consortium and the National Institutes of Health (NIH) Tuberculosis Transformative Science Group (TB TSG).

As noted in the document, there are several challenges related to the decades-old TB drugs, drug combinations, and treatment regimens in use today. These challenges warrant an urgent response to spur innovation in pharmaceutical development, clinical protocols, and health service delivery. The duration and complexity of today's TB treatments results in nonadherence and suboptimal clinical response, which in turn fuels prolonged disease, the emergence of drug resistance, and subsequent TB transmission. Moreover, adverse events associated with current regimens further contribute to nonadherence, and HIV co-infection can raise toxicity profiles and increase the risk of adverse drug interactions. Compounding these challenges, nationwide shortages of first- and second-line TB drugs and reagents, including isoniazid, ethambutol, and TB skin test antigen, have hampered our ability to properly diagnose and treat TB patients. Meanwhile, multi-drug resistant (MDR) TB and even extensively drug-resistant (XDR) TB continue to pose a substantial public health threat in the U.S. and globally.


For the first time since the 1960s, new TB drugs and shorter regimens are emerging that could significantly alter the course of treatment, saving lives and improving the quality of life for those living with TB. It is vital that this momentum continues.

The draft guidance represents a major step forward for the clinical development of improved TB treatment regimens. Many of the parameters outlined in the document

are already in use today by IDSA members leading various TB clinical trials. The guidance provides much-needed clarity for sponsors interested in TB product development, and this is especially important considering how few companies remain active in this therapeutics area. IDSA welcomes FDA's alignment with leading clinical researchers, and we endorse the guidance with enthusiasm.

Thank you for your efforts to advance TB treatment discovery and development. Should you have any questions, please contact John Billington, IDSA's Senior Program Officer for Health Policy at [jbillington@idsociety.org](mailto:jbillington@idsociety.org) or 703-299-0015.

Sincerely,

A handwritten signature in black ink that reads "Barbara E. Murray M.D." The signature is written in a cursive style with a large, looped initial 'B'.

Barbara E. Murray, MD, FIDSA  
President, IDSA